CompletedPhase 1

Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans

Switzerland12 participantsStarted 2011-11

Plain-language summary

The aim is to further establish a physiological role for GLP-1 as an endogenous satiety signal by examining the effect of the specific GLP-1 receptor antagonist exendin (9-39) on appetite and food intake in healthy male subjects.

Who can participate

Age range18 Years – 45 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy male subject with a BMI of 19-25 m2/kg
✓. Stable body weight for at least three months
✓. Normal eating habits
✓. Age between 18 and 45 years
✓. Sufficient understanding of the German language
✓. Subjects understand the procedures and the risks associated with the study
✓. Participants must be willing to adhere to the protocol and sign the consent form

Exclusion criteria

✕. Participation in another clinical trial (currently or within the last 30 days)
✕. Smoking
✕. Substance abuse
✕. Regular intake of medications (except for oral contraceptives)
✕. Chronic or acute medical condition including clinically relevant abnormality in physical exam or laboratory values
✕. History of gastrointestinal disorders
✕. Food allergies

What they're measuring

Effect of exendin(9-39)on total calorie intake

Timeframe: 60 min test meal

Effect of exendin(9-39) on total fluid intake

Timeframe: 60 min test meal

Effect of exendin(9-39)on meal duration during an ad libitum test meal.

Timeframe: 60 min test meal

Trial details

NCT IDNCT01900340

SponsorUniversity Hospital, Basel, Switzerland

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Appetite and General Nutritional Disorders trials